Elizabeth Preston is a science writer and editor in the Boston area. She has written for The Atlantic, Wired, Jezebel and the Boston Globe, among other publications. Her blog, Inkfish, is published by Discover.
Elizabeth Preston
From this contributor
Test paints quick picture of intelligence in autism
A picture-based test is a fast and flexible way to assess intelligence in large studies of people with autism.
Test paints quick picture of intelligence in autism
New atlases chart early brain growth in monkeys
A collection of brain scans from monkeys aged 2 weeks to 12 months reveals how their brain structures and nerve tracts develop over time.
New atlases chart early brain growth in monkeys
Work in progress: An inside look at autism’s job boom
Splashy corporate initiatives aim to hire people with autism, but finding and keeping work is still a struggle for those on the spectrum. Can virtual avatars and for-profit startups help?
Work in progress: An inside look at autism’s job boom
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.